{"schema_version":"secwatch.filing_event.v1","accession":"0001299130-23-000093","form_type":"8-K","ticker":"PACB","cik":"0001299130","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.510733+00:00","generated_at":"2026-06-12T12:03:35.562181+00:00","sec_items":["2.02","3.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PacBio Q2 revenue $47.6M (+34% YoY); acquires Apton for up to $110M; Onso shipments start","bullets":["Q2 revenue $47.6M (+34% YoY); Revio drove record revenue with 45 systems shipped.","Net loss $69.8M ($0.28 GAAP EPS); non-GAAP net loss $65.6M ($0.26).","Acquired Apton Biosystems for ~$85M in stock plus up to $25M contingent milestone, valued up to ~$110M.","Commercial shipments of Onso short-read sequencer commenced; first customer shipment today.","Cash and investments $829.9M at June 30; issued $441M 1.375% convertible notes due 2030."],"urls":{"canonical":"https://secwatch.observer/filing/0001299130-23-000093","json":"https://secwatch.observer/filing/0001299130-23-000093.json","markdown":"https://secwatch.observer/filing/0001299130-23-000093.md","text":"https://secwatch.observer/filing/0001299130-23-000093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1299130/000129913023000093/0001299130-23-000093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1299130/000129913023000093/pacb-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T12:03:35.562181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"836dafc67887f8242ca67434cc474c687fcae1f5","claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the quarter ended June 30, 2023 results: revenue $47.6 million, net income $69.8 million, EPS $0.28.","evidence_excerpt":"Revenue of $47.6 million, a 34% increase compared with $35.5 million in the prior-year period. • Recognized revenue on 47 sequencing systems in the second quarter, including 45 Revio systems and 2 Sequel IIe systems, compared to 36 Sequel II/IIe systems in the prior-year period. • Instrument revenue of $29.9 million compared with $15.6 million in the prior-year period. • Consumables revenue of $13.7 million compared with $14.6 million in the prior-year period. • Service and other revenue of $3.9 million compared with $5.3 million in the prior-year period. Gross profit for the second quarter of 2023 was $15.5 million, representing a 4% decrease compared with $16.2 million for the second quarter of 2022 and a gross margin of 33% in the second quarter of 2023 compared to 46% for the second quarter of 2022. Non-GAAP gross profit for the second quarter of 2023 was $15.7 million and represented a non-GAAP gross margin of 33% in the second quarter of 2023, compared to a non-GAAP gross profit","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913023000093/0001299130-23-000093-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$47.6 million"},{"label":"Net income","value":"$69.8 million"},{"label":"EPS","value":"$0.28"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}